These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 33140542

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long interventional study.
    Stefanakis K, Kokkinos A, Argyrakopoulou G, Konstantinidou SK, Simati S, Kouvari M, Kumar A, Kalra B, Kumar M, Bontozoglou N, Kyriakopoulou K, Mantzoros CS.
    Diabetes Obes Metab; 2023 Sep; 25(9):2561-2574. PubMed ID: 37246799
    [Abstract] [Full Text] [Related]

  • 3. Methods paper: Performance characteristics of novel assays for circulating levels of proglucagon-derived peptides and validation in a placebo controlled cross-over randomized clinical trial.
    Perakakis N, Kalra B, Angelidi AM, Kumar A, Gavrieli A, Yannakoulia M, Mantzoros CS.
    Metabolism; 2022 Apr; 129():155157. PubMed ID: 35114286
    [Abstract] [Full Text] [Related]

  • 4. Circulating levels of five proglucagon-derived peptides in response to intravenous or oral glucose or lipids and to a mixed-meal in subjects with normal weight, overweight, and obesity.
    Perakakis N, Kokkinos A, Angelidi AM, Tsilingiris D, Gavrieli A, Yannakoulia M, Tentolouris N, Mantzoros CS.
    Clin Nutr; 2022 Sep; 41(9):1969-1976. PubMed ID: 35961260
    [Abstract] [Full Text] [Related]

  • 5. Circulating levels of all proglucagon-derived peptides are differentially regulated postprandially by obesity status and in response to high-fat meals vs. high-carbohydrate meals.
    Stefanakis K, Kokkinos A, Simati S, Argyrakopoulou G, Konstantinidou SK, Kouvari M, Kumar A, Kalra B, Mantzoros CS.
    Clin Nutr; 2023 Aug; 42(8):1369-1378. PubMed ID: 37418844
    [Abstract] [Full Text] [Related]

  • 6. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.
    Mashayekhi M, Nian H, Mayfield D, Devin JK, Gamboa JL, Yu C, Silver HJ, Niswender K, Luther JM, Brown NJ.
    Diabetes; 2024 Jan 01; 73(1):38-50. PubMed ID: 37874653
    [Abstract] [Full Text] [Related]

  • 7. GLP-2 receptor signaling controls circulating bile acid levels but not glucose homeostasis in Gcgr-/- mice and is dispensable for the metabolic benefits ensuing after vertical sleeve gastrectomy.
    Patel A, Yusta B, Matthews D, Charron MJ, Seeley RJ, Drucker DJ.
    Mol Metab; 2018 Oct 01; 16():45-54. PubMed ID: 29937214
    [Abstract] [Full Text] [Related]

  • 8. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
    Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agersø H, Veldhuis J, Pørksen N, Schmitz O.
    Diabetes; 2002 Feb 01; 51(2):424-9. PubMed ID: 11812750
    [Abstract] [Full Text] [Related]

  • 9. Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.
    Mok J, Adeleke MO, Brown A, Magee CG, Firman C, Makahamadze C, Jassil FC, Marvasti P, Carnemolla A, Devalia K, Fakih N, Elkalaawy M, Pucci A, Jenkinson A, Adamo M, Omar RZ, Batterham RL, Makaronidis J.
    JAMA Surg; 2023 Oct 01; 158(10):1003-1011. PubMed ID: 37494014
    [Abstract] [Full Text] [Related]

  • 10. Response to lowering plasma glucose is characterised by decreased oxyntomodulin: Results from a randomised controlled trial.
    Liu Y, Kimita W, Bharmal SH, Petrov MS.
    Diabetes Metab Syndr; 2024 Jun 01; 18(6):103052. PubMed ID: 38901179
    [Abstract] [Full Text] [Related]

  • 11. Proglucagon-Derived Peptides as Therapeutics.
    Lafferty RA, O'Harte FPM, Irwin N, Gault VA, Flatt PR.
    Front Endocrinol (Lausanne); 2021 Jun 01; 12():689678. PubMed ID: 34093449
    [Abstract] [Full Text] [Related]

  • 12. Biologic actions and therapeutic potential of the proglucagon-derived peptides.
    Drucker DJ.
    Nat Clin Pract Endocrinol Metab; 2005 Nov 01; 1(1):22-31. PubMed ID: 16929363
    [Abstract] [Full Text] [Related]

  • 13. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop.
    Roberge JN, Brubaker PL.
    Endocrinology; 1993 Jul 01; 133(1):233-40. PubMed ID: 8319572
    [Abstract] [Full Text] [Related]

  • 14. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
    Flint A, Kapitza C, Hindsberger C, Zdravkovic M.
    Adv Ther; 2011 Mar 01; 28(3):213-26. PubMed ID: 21340616
    [Abstract] [Full Text] [Related]

  • 15. Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic condition.
    Streckel E, Braun-Reichhart C, Herbach N, Dahlhoff M, Kessler B, Blutke A, Bähr A, Übel N, Eddicks M, Ritzmann M, Krebs S, Göke B, Blum H, Wanke R, Wolf E, Renner S.
    J Transl Med; 2015 Feb 25; 13():73. PubMed ID: 25890210
    [Abstract] [Full Text] [Related]

  • 16. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
    Baggio LL, Huang Q, Brown TJ, Drucker DJ.
    Gastroenterology; 2004 Aug 25; 127(2):546-58. PubMed ID: 15300587
    [Abstract] [Full Text] [Related]

  • 17. Enteroglucagon.
    Holst JJ.
    Annu Rev Physiol; 1997 Aug 25; 59():257-71. PubMed ID: 9074764
    [Abstract] [Full Text] [Related]

  • 18. [Prognostic factors for the carbohydrate metabolism normalization in patients with type 2 diabetes mellitus and obesity using liraglutide 3.0 mg per day].
    Sklyanik IA, Shestakova MV.
    Ter Arkh; 2021 Oct 15; 93(10):1203-1208. PubMed ID: 36286822
    [Abstract] [Full Text] [Related]

  • 19. Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study.
    Kim SH, Liu A, Ariel D, Abbasi F, Lamendola C, Grove K, Tomasso V, Reaven G.
    Diabetologia; 2014 Mar 15; 57(3):455-62. PubMed ID: 24326527
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.